Effect of Neoadjuvant Hormonal Treatment on the Necessity of Secondary Radiotherapy in Patients Undergoing Radical Prostatectomy for High-Risk Prostate Cancer

• Published in: Üroonkoloji bülteni Vol. 20; no. 4; pp. 219 - 224
• Main Authors: Berczi, Csaba, Docs, Janos, Thomas, Ben, Bacso, Zsolt, Flasko, Tibor
• Format: Journal Article
• Language: English
• Published: Istanbul Galenos Publishing House 01.12.2021
• Subjects: Androgens; Associations; Cancer surgery; Cancer therapies; Histology; Magnetic resonance imaging; Patients; Prostate cancer; Radiation therapy; Surgery; Tumors; Urological surgery; Urology
• ISSN: 2147-2122; 2147-2270
• DOI: 10.4274/uob.galenos.2021.2021.9.1

Objective: The goal of this study was to see how neoadjuvant hormonal therapy affected the frequency of secondary radiotherapy after radical prostatectomy for high-risk prostate tumors. Materials and Methods: Further, 527 patients with high-risk prostate cancer were divided into two groups. In group 1 (n=139), neoadjuvant androgen deprivation treatment was administered prior to surgery, whereas it was not applied preoperatively in group 2 (n=388). Results: Biochemical progression was observed in 27 patients (19.4%) in group 1 and 54 patients (13.9%) in group 2 (p=0.148). Adjuvant and salvage irradiation were administered to patients with pT2 cancer who received neoadjuvant hvsormonal therapy in 17.3% and 7.1% of the cases, respectively, whereas in cases without prior neoadjuvant treatment, adjuvant and salvage irradiation were administered in 21.6% and 5.4% (p=0.370 and p=0.523). Clinically advanced cancer patients who received neoadjuvant hormonal treatment had adjuvant and salvage irradiation in 34.1% and 2.4% of the cases, whereas patients who did not receive neoadjuvant treatment had adjuvant and salvage radiotherapy in 35.9% and 7.6% of the cases (p=0.856 and p=0.278). Conclusion: Although neoadjuvant hormonal treatment improved local tumor control, it did not reduce the frequency of secondary radiotherapy significantly. Overall, and in the cT2 subgroup, there was a relative decrease in the number of adjuvant treatments compared to salvage treatments in neoadjuvant-treated patients.